Xenon Seven

Xenon Seven

Director, Field Effectiveness & Operations

Boston · Director

Sponsorship not specifiedDetected 8 days ago
SnowflakeRESTMachine LearningData VisualizationProject ManagementStakeholder ManagementSalesforceCRMSalesAccount ManagementPerformance ManagementClinical TrialsPatient CareLeadershipCommunication

About the role

  • This role will serve as the operational engine for field readiness, field execution, and launch performance optimization across customer-facing commercial teams.
  • This position reports to the Vice President, Commercial Operations, and will be based out of Boston, MA, USA in our Needham office.
  • Hybrid positions require a minimum of two onsite days per week.

Responsibilities

  • Build and operationalize Xenon's field effectiveness infrastructure to support launch readiness, launch execution, and post-launch optimization across commercial field teams
  • Serve as a primary Commercial Operations partner to field strategy and leadership, ensuring field execution needs are anticipated, prioritized, and translated into operational and scalable solutions.
  • Develop and produce field execution analytics and identify gaps in execution quality, adoption, and performance variability
  • Collaborate on strategy and lead operational execution of territory alignment, targeting refinement, field deployment support, and related vendor workstreams in partnership with Commercial Analytics, Sales leadership, Market Access, IT, and external partners
  • Translate field design, account segmentation, and targeting logic into field-ready CRM workflows, call plans, execution guidance, and KPIs
  • Serve as the business owner or key Commercial Operations partner for field-facing systems and tools, including CRM, field reporting, account planning tools, dashboards, and related technology platforms
  • Collaborate on business requirements for CRM workflows, field reporting, dashboards, account planning tools, and other field enablement capabilities
  • Lead incentive compensation operations in partnership with Sales leadership, Finance, HR, Legal, Compliance, and Analytics

Requirements

  • 10+ years of progressive experience in pharmaceutical, biotech, or life sciences commercial operations, sales operations, field effectiveness, sales force effectiveness, field analytics, or related roles
  • Strong knowledge of field operations capabilities, including CRM, territory alignment, targeting, field deployment, call planning, incentive compensation, field reporting, and performance management
  • Demonstrated ability to translate commercial strategy into scalable operational processes, tools, dashboards, and execution plans
  • Strong understanding of field-facing technology platforms, CRM workflows, business requirements, data quality, and reporting adoption
  • Strong analytical orientation with the ability to interpret field performance, identify execution gaps, and communicate actionable recommendations to senior leaders
  • Experience with Veeva CRM, Salesforce, Power BI, Tableau, Snowflake, IQVIA, Symphony, claims data, specialty pharmacy data, hub/patient services data, or related commercial data assets
  • Experience designing or operationalizing incentive compensation plans, field force alignment models, call planning, field dashboards, account planning tools, or QBR processes
  • Bachelor's degree required; advanced degree in business, life sciences, analytics, healthcare, or related field preferred
  • Demonstrated experience supporting launch readiness or commercial launch execution, ideally in a specialty, rare disease, neurology, CNS, or complex market environment
  • Experience partnering with Sales, Marketing, Market Access, Medical Affairs, Analytics, IT, Finance, HR, Legal, Compliance, and external vendors
  • Practical understanding of pharmaceutical compliance considerations related to field operations, CRM, data capture, incentive compensation, and field communications
  • Excellent project management, cross-functional leadership, executive communication, and stakeholder management skills
  • Ability to thrive in a fast-paced, evolving, build-mode environment with high ambiguity and competing priorities
  • Experience with AI, machine learning, automation, or advanced analytics use cases in commercial operations, field effectiveness, omnichannel execution, or launch performance management

Nice to have

  • Bachelor's degree required

Compensation

  • The ideal candidate is a hands-on builder with strong field operations, commercial operations, CRM, field analytics, incentive compensation, targeting, and launch-readiness experience.

Benefits

  • Partner with Field Strategy, Marketing, Market Access, Medical, Data Strategy & Analytics, IT, Finance, HR, Legal, and Compliance to translate launch strategy into field-ready processes, tools, and operating rhythms

Company info

  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • What We Do:
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
  • We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
  • Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
  • In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
  • Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
  • We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
  • In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
  • We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.
  • Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
Apply directly at Xenon Seven →Create a free account for alerts like thisView Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.